Literature DB >> 29414249

Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease.

Juan Pablo Arab1,2, Marco Arrese1,3, Michael Trauner4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide and an important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing prevalence of this disease and of its aggressive form nonalcoholic steatohepatitis (NASH) will require novel therapeutic approaches based on a profound understanding of its pathogenesis to halt disease progression to advanced fibrosis or cirrhosis and cancer. The pathogenesis of NAFLD involves a complex interaction among environmental factors (i.e., Western diet), obesity, changes in microbiota, and predisposing genetic variants resulting in a disturbed lipid homeostasis and an excessive accumulation of triglycerides and other lipid species in hepatocytes. Insulin resistance is a central mechanism that leads to lipotoxicity, endoplasmic reticulum stress, disturbed autophagy, and, ultimately, hepatocyte injury and death that triggers hepatic inflammation, hepatic stellate cell activation, and progressive fibrogenesis, thus driving disease progression. In the present review, we summarize the currently available data on the pathogenesis of NAFLD, emphasizing the most recent advances. A better understanding of NAFLD/NASH pathogenesis is crucial for the design of new and efficient therapeutic interventions.

Entities:  

Keywords:  NAFLD; NASH; cirrhosis; fibrosis; insulin resistance; nonalcoholic fatty liver; nonalcoholic steatohepatitis; pathogenesis; steatosis

Mesh:

Year:  2018        PMID: 29414249     DOI: 10.1146/annurev-pathol-020117-043617

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  112 in total

1.  Yes-Associated Protein in Kupffer Cells Enhances the Production of Proinflammatory Cytokines and Promotes the Development of Nonalcoholic Steatohepatitis.

Authors:  Kyoungsub Song; Hyunjoo Kwon; Chang Han; Weina Chen; Jinqiang Zhang; Wenbo Ma; Srikanta Dash; Chandrashekhar R Gandhi; Tong Wu
Journal:  Hepatology       Date:  2020-04-11       Impact factor: 17.425

2.  Non-alcoholic fatty liver disease: a pandemic disease with multisystem burden.

Authors:  Somaya Albhaisi; Danny Issa; Naim Alkhouri
Journal:  Hepatobiliary Surg Nutr       Date:  2018-10       Impact factor: 7.293

3.  Soluble (pro)renin receptor treats metabolic syndrome in mice with diet-induced obesity via interaction with PPARγ.

Authors:  Fei Wang; Renfei Luo; Chang-Jiang Zou; Shiying Xie; Kexin Peng; Long Zhao; Kevin T Yang; Chuanming Xu; Tianxin Yang
Journal:  JCI Insight       Date:  2020-04-09

4.  Exosomal miR-199a-5p promotes hepatic lipid accumulation by modulating MST1 expression and fatty acid metabolism.

Authors:  Yuhan Li; Yansong Luan; Jianning Li; Hui Song; Yan Li; Hi Qi; Bo Sun; Peng Zhang; Xianxian Wu; Xing Liu; Yanhui Yang; Wufan Tao; Lei Cai; Zhiwei Yang; Yi Yang
Journal:  Hepatol Int       Date:  2020-10-10       Impact factor: 6.047

Review 5.  [Role of lipophagy in the regulation of lipid metabolism and the molecular mechanism].

Authors:  Linna Shi; Ke Wang; Yudi Deng; Yingna Wang; Shuangling Zhu; Xushan Yang; Wenzhen Liao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-07-30

6.  Dual roles of ULK1 (unc-51 like autophagy activating kinase 1) in cytoprotection against lipotoxicity.

Authors:  Jeong Su Park; Da Hyun Lee; Yu Seol Lee; Eunji Oh; Kwang-Hee Bae; Kyoung-Jin Oh; Hyunmi Kim; Soo Han Bae
Journal:  Autophagy       Date:  2019-04-09       Impact factor: 16.016

Review 7.  Non-alcoholic fatty liver disease: Insights from sphingolipidomics.

Authors:  David J Montefusco; Jeremy C Allegood; Sarah Spiegel; L Ashley Cowart
Journal:  Biochem Biophys Res Commun       Date:  2018-05-21       Impact factor: 3.575

Review 8.  Role of the mTOR-autophagy-ER stress pathway in high fructose-induced metabolic-associated fatty liver disease.

Authors:  Ya-Lin Wang; Xiu Zhou; Dong-Li Li; Ji-Ming Ye
Journal:  Acta Pharmacol Sin       Date:  2021-03-17       Impact factor: 6.150

9.  Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management.

Authors:  Hersh Shroff; Lisa B VanWagner
Journal:  Curr Hepatol Rep       Date:  2020-06-29

10.  Hepatocyte-specific expression of human carboxylesterase 2 attenuates nonalcoholic steatohepatitis in mice.

Authors:  Yanyong Xu; Xiaoli Pan; Shuwei Hu; Yingdong Zhu; Fathima Cassim Bawa; Yuanyuan Li; Liya Yin; Yanqiao Zhang
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-12-16       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.